




The relative strengths and weaknesses of Regeneron Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regeneron Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Regeneron Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 327%, being 84% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	1,796,934
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	298,835
Liabilities, Non-Current	11,330
Other Assets	627,096
Other Compr. Net Income	-22
Other Expenses	444,353
Other Liabilities	688,772
Other Net Income	-46,668
Other Revenues	2,104,745
Property and Equipment	526,983
Research and Development	859,947
Selling, General and Administrative Expense	329,415

Output Variable	Value in 1000 USD
Assets	2,951,013
Liabilities	998,937
Expenses	1,633,715
Revenues	2,104,745
Stockholders Equity	1,952,076
Net Income	424,362
Comprehensive Net Income	424,351
BaseVar	3,867,550
ECR before LimitedLiability	237%
Economic Capital Ratio	327%